Jiazhen Chen1, Shuo Zhang2, Peng Cui1, Wanliang Shi2, Wenhong Zhang1, Ying Zhang1,2. 1. Key Lab of Molecular Virology, Institute of Medical Microbiology, Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China. 2. Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Abstract
OBJECTIVES: d-Cycloserine is an important second-line drug used to treat MDR- and XDR-TB. However, the mechanisms of resistance to d-cycloserine are not well understood. Here we investigated the molecular basis of d-cycloserine resistance using in vitro-isolated resistant mutants. METHODS: Mycobacterium tuberculosis H37Rv was subjected to mutant selection on 7H11 agar plates containing varying concentrations of d-cycloserine. A total of 18 d-cycloserine-resistant mutants were isolated and subjected to WGS. The identified mutations associated with d-cycloserine resistance were confirmed by PCR and Sanger sequencing. RESULTS: We identified mutations in 16 genes that are associated with d-cycloserine resistance. Interestingly, we found mutations only in alr (rv3423c) encoding alanine racemase, but not in other known d-cycloserine resistance-associated genes such as ddl, cycA or ald. Instead, we identified 13 new genes [rv0059, betP (rv0917), rv0221, rv1403c, rv1683, rv1726, gabD2 (rv1731), rv2749, sugI (rv3331), hisC2 (rv3772), the 5' intergenic region of rv3345c and rv1435c, and the 3' region of rv0759c] that had solo mutations associated with d-cycloserine resistance. Our findings indicate that the mechanisms of d-cycloserine resistance are more complex than previously thought and involve genes participating in different cellular functions such as lipid metabolism, methyltransferase, the stress response and transport systems. CONCLUSIONS: New mutations in diverse genes associated with d-cycloserine resistance have been identified that shed new light on the mechanisms of action and resistance of d-cycloserine. Future studies are needed to verify these findings in clinical strains so that molecular detection of d-cycloserine resistance for improved treatment of MDR-TB can be developed.
OBJECTIVES: d-Cycloserine is an important second-line drug used to treat MDR- and XDR-TB. However, the mechanisms of resistance to d-cycloserine are not well understood. Here we investigated the molecular basis of d-cycloserine resistance using in vitro-isolated resistant mutants. METHODS: Mycobacterium tuberculosis H37Rv was subjected to mutant selection on 7H11 agar plates containing varying concentrations of d-cycloserine. A total of 18 d-cycloserine-resistant mutants were isolated and subjected to WGS. The identified mutations associated with d-cycloserine resistance were confirmed by PCR and Sanger sequencing. RESULTS: We identified mutations in 16 genes that are associated with d-cycloserine resistance. Interestingly, we found mutations only in alr (rv3423c) encoding alanine racemase, but not in other known d-cycloserine resistance-associated genes such as ddl, cycA or ald. Instead, we identified 13 new genes [rv0059, betP (rv0917), rv0221, rv1403c, rv1683, rv1726, gabD2 (rv1731), rv2749, sugI (rv3331), hisC2 (rv3772), the 5' intergenic region of rv3345c and rv1435c, and the 3' region of rv0759c] that had solo mutations associated with d-cycloserine resistance. Our findings indicate that the mechanisms of d-cycloserine resistance are more complex than previously thought and involve genes participating in different cellular functions such as lipid metabolism, methyltransferase, the stress response and transport systems. CONCLUSIONS: New mutations in diverse genes associated with d-cycloserine resistance have been identified that shed new light on the mechanisms of action and resistance of d-cycloserine. Future studies are needed to verify these findings in clinical strains so that molecular detection of d-cycloserine resistance for improved treatment of MDR-TB can be developed.
Authors: John B Bruning; Ana C Murillo; Ofelia Chacon; Raúl G Barletta; James C Sacchettini Journal: Antimicrob Agents Chemother Date: 2010-10-18 Impact factor: 5.191
Authors: K M Kam; A Sloutsky; C W Yip; N Bulled; K J Seung; M Zignol; M Espinal; S J Kim Journal: Int J Tuberc Lung Dis Date: 2010-03 Impact factor: 2.373
Authors: Fritz Titgemeyer; Johannes Amon; Stephan Parche; Maysa Mahfoud; Johannes Bail; Maximilian Schlicht; Nadine Rehm; Dietmar Hillmann; Joachim Stephan; Britta Walter; Andreas Burkovski; Michael Niederweis Journal: J Bacteriol Date: 2007-06-08 Impact factor: 3.490
Authors: Claudio U Köser; Josephine M Bryant; Jennifer Becq; M Estée Török; Matthew J Ellington; Marc A Marti-Renom; Andrew J Carmichael; Julian Parkhill; Geoffrey P Smith; Sharon J Peacock Journal: N Engl J Med Date: 2013-07-18 Impact factor: 91.245
Authors: Keira A Cohen; Abigail L Manson; Christopher A Desjardins; Thomas Abeel; Ashlee M Earl Journal: Genome Med Date: 2019-07-25 Impact factor: 11.117
Authors: Juan Espinosa-Pereiro; Adrian Sánchez-Montalvá; Maria Luisa Aznar; Maria Espiau Journal: Medicina (Kaunas) Date: 2022-01-26 Impact factor: 2.430